- 1 Title: Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium
- 2 pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy:
- 3 Results of an open-label, prospective, exploratory clinical study
- 4 **Running Title**: N-163 beta glucan as disease modifying agent in DMD

5 Authors:

- 6 Kadalraja Raghavan<sup>1,,2,3</sup> (<u>drkraghavan@nichimail.jp</u>)
- 7 Vidyasagar Devaprasad Dedeepiya<sup>4</sup> (<u>drddp@nichimail.jp</u>)
- 8 Subramaniam Srinivasan<sup>4</sup> (<u>masala76@gmail.com</u>)
- 9 Subramanian Pushkala<sup>5</sup> (<u>pushkala66m@gmail.com</u>)
- 10 Sudhakar Subramanian<sup>6</sup> (<u>drsudhakar77@gmail.com</u>)
- 11 Nobunao Ikewaki<sup>7,8</sup> (<u>nikewaki@phoenix.ac.jp</u>)
- 12 Masaru Iwasaki<sup>9</sup> (<u>miwasaki@yamanashi.ac.jp</u>)
- 13 Rajappa Senthilkumar<sup>10</sup> (<u>rsk@nichimail.jp</u>)
- 14 Senthilkumar Preethy<sup>10</sup> (<u>drspp@nichimail.jp</u>)
- 15 Samuel JK Abraham<sup>4,9,11</sup> (<u>drsam@nichimail.jp</u>)

# 16 Affiliations:

- Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for
   Advanced Recovery and Education (JAICARE), Madurai, India
- Department of Paediatric Neurology, Kenmax Medical Service Private Limited,
   Madurai, India.
- 21 3. Department of Paediatric Neurology, Sarvee Integra Private Limited, Chennai, India.

22	4.	Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative
23		Medicine (NCRM), Chennai, India.
24	5.	Department of Immunology, The Tamil Nadu Dr. M.G.R. Medical University,
25		Chennai, 600032, India.
26	6.	Department of Anesthesia and Pain service, Toronto Western Hospital, 399 Bathurst
27		street Toronto, Ontario, Canada.
28	7.	Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
29	8.	Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
30	9.	Centre for Advancing Clinical Research (CACR), University of Yamanashi - School
31		of Medicine, Chuo, Japan.
32	10.	Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine
33		(NCRM), Chennai, India.
34	11.	Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,
35		Japan
36 Co	orre	sponding author information:
37	Dr	Samuel JK Abraham,
38	ΠI	Department of Surgery & CACR,
39	Un	iversity of Yamanashi, Faculty of Medicine
40	Ad	dress for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan
41	En	ail id- <u>drsam@nichimail.jp</u> ; Alternate email id: <u>drspp@nichimail.jp</u>
42	Fax	x: +81-55-235-7569
43		

### 45 **Declarations:**

#### 46 *Ethics approval and consent to participate*

- 47 The study was registered in Clinical trials registry of India, CTRI/2021/05/033346.
- 48 Registered on 5th May, 2021. The study was approved by the Institutional Ethics Committee
- 49 (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.

### 50 Consent for publication

51 Not applicable

## 52 Availability of data and material

All data generated or analysed during this study are included in the article itself.

#### 54 Funding

55 No external funding was received for the study

#### Competing interests

Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of novel beta glucans using different strains of Aureobasidium pullulans and also an applicant to several patents of relevance to these beta glucans.

### 56 Authors' contributions

KR, NI and SA. contributed to conception and design of the study. KR, RS and NI helped in data collection and analysis. SA and SP drafted the manuscript. VD, SS, SUP, SSU and MI performed critical revision of the manuscript. All authors read and approved the final manuscript.

62

#### 63 Acknowledgements

The authors would like to dedicate this paper to the memory of Mr. Takashi Onaka, who passed away on the 1st of June, 2022 at the age of 90 years, who played an instrumental role in successfully culturing an industrial scale up of AFO-202 and N-163 strains of Aureobasidium pullulans after their isolation by Prof. Noboru Fujii, producing the novel beta glucan described in this study.

69 They thank

The Government of Japan and the Prefectural Government of Yamanashi for a special
 loan and M/s Yamanashi Chuo Bank for processing the transactions.

Ms. Sunitha, Mr. Vincent, Mr. Shivakumar (Physiotherapist), Dr. Madhankumar and
the staff of Kenmax & Sarvee Integra, for their assistance during the clinical study and data
collection of the manuscript.

75 3. Fr. Francis Xavier, Fr. Vargheesh Antony, Fr. Marianathan and Mr Jeyachandran of
76 JAICARE for their support during the clinical study.

4. Mr. Mitsuru Nagataki (Sophy Inc, Kochi, Japan), for necessary technicalclarifications.

Mr. Yoshio Morozumi and Ms. Yoshiko Amikura of GN Corporation, Japan for theirliaison assistance with the conduct of the study.

81 6. Loyola-ICAM College of Engineering and Technology (LICET) for their support to82 our research work.

83

84

85

87

### 88 Abstract

Background: This trial is to evaluate the effects of supplementation of Aureobasidium
pullulans-N-163 strain produced 1,3-1,-6 beta glucan in young patients with Duchenne
muscular dystrophy (DMD).

92 Methods:

Twenty-seven male subjects aged 5-19 years with DMD were included, nine in the control arm and 18 in the treatment arm to receive N-163 beta glucan along with conventional therapies for 45 days. While performing the analysis, patients were stratified into: those not administered steroids (Steroid -ve) (Control, n=5; treatment, n=9), those administered steroids (Steroid +ve) (Control, n=4; treatment, n=9), which was not pre-specified.

98 **Results:** 

99 IL-6 showed a significant decrease in the N-163 Steroid -ve group, from 7.2  $\pm$  1.2 pg/ml to 100  $2.7 \pm 0.03$  pg/ml. IL-13 decreased in both treatment groups—from  $157.76 \pm 148.68$  pg/ml to 101  $114.08 \pm 81.5$  pg/ml (N-163 Steroid -ve) and from  $289.56 \pm 232.88$  pg/ml to  $255.56 \pm 214.13$ 102 pg/ml (N-163 Steroid +ve). TGF- $\beta$  levels showed a significant decrease in the N-163 Steroid 103 -ve group. Dystrophin levels increased by up to 32% in both treatment groups. Medical 104 research council (MRC) grading showed slight improvement in muscle strength improvement 105 in 12 out of 18 patients (67%) in the treatment group and four out of nine (44%) subjects in 106 the control group.

107 **Conclusion:** 

Supplementation with the N-163 beta glucan food supplement produced beneficial effects: a
 significant decrease in inflammation and fibrosis markers, increase in serum dystrophin and

110	slight improvement	in muscle	strength in	DMD	subjects	over 45	days,	thus	making	this	a
-----	--------------------	-----------	-------------	-----	----------	---------	-------	------	--------	------	---

111 potential adjunct treatment for DMD after validation.

# 112 **Trial registration:**

- 113 The study was registered in Clinical trials registry of India, CTRI/2021/05/033346.
- 114 Registered on 5th May, 2021.
- 115
- **Keywords:** Duchenne muscular dystrophy; N-163; beta glucan; disease modifying agent;
- 117 inflammation; fibrosis; dystrophin
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128

129 Introduction:

130 Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder 131 causing severe and progressive weakness of skeletal muscles, leading to loss of ambulation 132 along with concomitant impairment of cardiac and respiratory muscles and early mortality. 133 Mutations in the dystrophin gene, which cause total loss of the dystrophin protein [2], remain 134 the major underlying mechanism. Loss of dystrophin leads to damage of the myofibres' 135 plasma membranes and distorts the structural stability of the plasma, leading to weakness in 136 the myofibres. The weakened myofibres cannot withstand the contraction and relaxation 137 cycles occurring during muscle function. The damage to the membrane releases the 138 cytoplasmic contents, triggering the immune system and causing further muscle fibre 139 damage, weakness and ultimately death [3]. A chronic proinflammatory state ensues, with 140 neutrophil infiltration and macrophages' phagocytosis of the degenerated tissue [3], 141 preventing repair of the muscle damage, which otherwise occurs in a highly orchestrated 142 manner for faster repair in other physiological conditions. The muscle is relatively immunologically privileged, with a low capacity to generate localized immune responses and 143 144 thus having low rates of abscess and granuloma formation [3]. Therefore, it becomes 145 essential to modulate the inflammation and immunity to resolve the chronic inflammatory 146 state in therapeutic approaches to DMD. Steroid therapy is the most commonly employed 147 immuno-modulatory treatment approach. However, side effects include weight gain, weak 148 bones, high blood pressure and behaviour changes in addition to muscle weakness and 149 atrophy in the long term [4,5]. Thus, there arises the need to develop strategies that will assist 150 in immunomodulation with lesser side effects. Nutritional supplements are a potential option. 151 Beside beta glucans yielding locomotor improvement in zebrafish models of DMD [6], a 1-152 3,1-6 beta glucan from the N-163 strain of the black yeast Aureobasidium pullulans has been 153 reported to mitigate inflammation, evident by decreases in anti-inflammatory markers such as 154 CD11b, serum ferritin, galectin-3 and fibrinogen. It also produces beneficial immuno-

155	modulation via a decrease in the neutrophil-to-lymphocyte ratio (NLR) and an increase in the
156	lymphocyte-to-CRP ratio (LCR) and leukocyte-to-CRP ratio (LeCR) in human healthy
157	volunteers [7]. Mitigation of lipotoxicity-associated inflammatory cascades in a mouse study
158	has also been reported [8]. Another study done in an animal model of non-alcoholic
159	steatohepatitis (NASH) showed a decrease in liver inflammation and accumulation of F4/80+
160	cells (macrophages associated with inflammation) [9] in the liver. The present exploratory
161	study is to evaluate the immunomodulatory efficacy of the N-163 strain of A. pullulans-
162	produced beta 1-3,1-,6 glucan in comparison with a conventional therapeutic regimen in
163	patients with DMD.

# 164 Methods:

This trial was an investigator-initiated, single-centre, randomized, open-label, prospective,
comparative clinical study of patients with DMD. The study was conducted over 45 days.
The two treatment arms included were:

*Treatment arm I*, control arm: Conventional treatment regimen comprising standard routine
physiotherapy for joint mobility along with medications, viz., T. calcium and vit. D 1000
with or without deflazacort (steroid) 6mg to 24 mg.

*Treatment arm II*, intervention: One sachet of N-163 beta glucan (15g gel) once daily along
with conventional treatment.

The stratification based on steroid was performed only during analysis of the data and wasnot pre-specified.

*Inclusion criteria:* Male subjects with molecular diagnosis of DMD aged 6-18 years who
were willing to participate in the study with written informed consent.

177	Exclusion criteria: Patients with a previous (within the past 1 month) or concomitant
178	participation in any other therapeutic trial; a known or suspected malignancy; any other
179	chronic disease or clinically relevant limitation of renal, liver or heart function according to
180	the discretion of the investigator.
181	Investigations:
182	The following tests were carried out after written consent was obtained from the study
183	subjects.
184	At baseline and at the end of the study (after 45 days):
185	• Background survey: gender, date of birth, age, habits, current medical history,
186	medication, treatment, allergies (to drugs and food), regular use of food for specified
187	health uses, functional foods, health foods, intake of foods rich in $\beta$ -glucan foods
188	containing beta-glucan and intake of immunity-boosting foods
189	• Medical history and physical measurements: height, weight, BMI, temperature
190	• Physiological examination: systolic blood pressure, diastolic blood pressure, pulse
191	rate
192	• ECG
193	• Muscle strength test using MRC grading [10]
194	• Six-minute walk test (6MWT) [11]
195	• North Star Ambulatory Assessment (NSAA) [12]
196	• Blood sampling and investigations for the levels of IL-6, IL-13, TGF- $\beta$ , creatinine
197	kinase (CK), titin, haptoglobin, TNF- $\alpha$ , dystrophin, cystatin in the blood and
198	myoglobin in the urine
199	• Subjects were contacted every week for drug compliance and recording of adverse
200	effects, if any

201

#### 202 Study subjects = 28

203 The study was designed as an exploratory study, so there were two intervention conditions:

204 one control and one test group. As the minimum number of participants required for

statistical comparisons within and between intervention conditions is four per intervention

- 206 condition, a total of 28 target study participants (10 in treatment arm I [control] group and 18
- 207 in treatment arm II [N-163]) were used. One patient was disqualified due to misrepresentation
- of diagnosis. The CONSORT flow diagram of the trial is shown in Figure 1.

### 209 Selection of study subjects

210 Study investigators and other investigators included study subjects who had consented to

211 participate in the study, met the selection criteria and not the exclusion criteria, and who were

judged to have no problem participating in the study.

## 213 Allocation of study subjects

- The person in charge of the allocation, as specified in the study protocol, allocated the study
- subjects to the two groups by simple randomization (1:2).

## 216 Primary outcome:

217 Observation of changes in the levels of IL-6 in serum and myoglobin levels in urine from the

218 baseline measured by ELISA.

### 219 Secondary outcome:

- Observation of changes in the levels of IL-13, TGF-β, CK, titin, dystrophin,
   haptoglobin and cystatin C in the serum measured by ELISA.
- Observation of changes in the muscle function tests

### • Monitoring for adverse effects

#### 224 ELISA:

225 The biomarkers were validated using sandwich enzyme immunoassay. ELISA kits were

- 226 purchased from different manufacturers and the assay details along with sensitivity are listed
- in Table 2. ELISAs were performed according to manufacturer's instructions and the serum
- 228 was diluted to fall within the linear range of each respective assay.

### 229 Statistical analysis:

All data were analysed using Excel statistics package analysis (Microsoft Office Excel) and Origin2021b software. All 27 randomized participants were included in safety and efficacy analysis sets. All statistical tests were performed at a significance level of 0.05 without correction for multiple comparisons or multiple outcomes. Non-parametric tests such as Mann-Whitney U test and Kruskal-Wallis tests were used.

235

### 236 **Results:**

Twenty-eight patients were screened and 27 were randomized to control (n = 9) and treatment

(n = 18). One patient was disqualified due to misrepresentation of diagnosis. The CONSORT

- flow diagram of the trial is shown in Figure 1.
- 240 Demographics are shown in Table 1.

241 The stratification of patients was as follows based on steroid administration during analysis:

- 242 Group I: Control group (n = 9);
- A. Steroids not administered (n = 5) (Steroid -ve)
- B. Steroids administered (n = 4) (Steroid +ve)

- 245 Group II: Treatment (N-163) group (n = 18);
- A. Steroids not administered (n = 9) (Steroid -ve)
- 247 C. Steroids administered (n = 9) (Steroid +ve)
- The mean  $\pm$  SD age for the total study population was  $11.18 \pm 3.86$  years (range 5-19 years).
- 249 The mean age across the groups were Control (Steroid-ve) -14.25 years; Control (Steroid
- 250 +ve) 13.6 years; N-163 (Steroid -ve) 9.6 years; N-163 (Steroid +ve) 11.87 years.
- However the difference was not statistically significant (P=0.316). The mean  $\pm$  SD body
- 252 weight was  $35.59 \pm 15.5$  kgs (range = 10 to 65 kgs).
- 253 No adverse events were reported. No clinically significant changes from baseline data were
- observed on physical examination or in vital signs—temperature, blood pressure, oxygen
- saturation, pulse rate or ECG (data not shown).

### 256 Biomarker levels:

- 257 Levels are expressed as mean  $\pm$  SD. In regard to the primary outcome, IL-6 showed decrease
- in both the control and the treatment groups. However, when the analysis was stratified for
- steroid administration, IL-6 showed the highest decrease in the N-163 Steroid -ve group,
- from a baseline value of  $7.2 \pm 1.2$  pg/ml to  $2.7 \pm 0.03$  pg/ ml post intervention and the
- difference was significant (p-value = 0.01) (Figure 2, 6).
- IL-13 increased in both control groups—from  $300.4 \pm 114.5$  pg/ml at baseline to  $550.732 \pm$
- 107.95 pg/ml post-intervention in the Steroid -ve group and from  $142 \pm 112.82 \text{ pg/ml}$  at
- baseline to  $263.5 \pm 99.38$  pg/ml post-intervention in the Steroid +ve group. It decreased in
- both the treatment groups—from  $157.76 \pm 148.68$  pg/ml at baseline to  $114.08 \pm 81.5$  pg/ml
- post-intervention and from  $289.56 \pm 232.88$  pg/ml at baseline to  $255.56 \pm 214.13$  pg/ml post-
- intervention. The difference was statistically significant (p-value = 0.006) (Figure 3, 6).

268	TGF- $\beta$ levels showed a significant decrease in the N-163 Steroid -ve group, from a baseline
269	value of 3302 $\pm$ 1895 pg/ml to 1325.66 $\pm$ 517 pg/ml post intervention, which was
270	significantly lower than all the other groups (p-value = $0.02$ ) (Figure 4, 6).
271	Dystrophin levels showed a significant increase in the N-163 Steroid -ve group, from a
272	baseline value of $3.01 \pm 1.58$ ng/ml to $4.01 \pm 1.44$ ng/ml post intervention, and the N-163
273	Steroid +ve group went from a baseline value of $3.15 \pm 2.43$ ng/ml to $3.78 \pm 2.17$ ng/ml post
274	intervention, which was significantly higher than the control groups (p-value = $0.0009$ )
275	(Figure 5, 6). The N-163 Steroid -ve group showed higher dystrophin expression than the N-
276	163 Steroid +ve group with the difference being significant (p-value = $0.01$ ). The percentage
277	increase in dystrophin levels in the treatment group was up to 32.8%.
278	Haptoglobin did not show much difference pre or post intervention in the treatment groups,
279	but it was marginally increased in the control group (Figure 7). CK increased in the treatment
280	groups (Figure 7). Urine myoglobin increased in the N-163 Steroid +ve group but decreased
281	in all the other groups (Figure 7).
282	Titin and cystatin C decreased in the N-163 Steroid +ve group and the control Steroid +ve
283	group, but the difference was not significant. TNF- $\alpha$ decreased in all the groups except the N-
284	163 Steroid -ve group (Figure 7).
285	The 6MWT and NSAA did not show any significant differences between the groups (Figure
286	8). The MRC grading showed slight improvement in 12 out of 18 patients (67%) in the
287	treatment group and only four out of nine (44%) subjects in the control group but it was not
288	statistically significant (p-value = $0.02$ ) (Table 3, Figure 8).
289	Discussion:

290 Current interventions for DMD, such as corticosteroids and rehabilitative care, help to 291 prolong survival up to the third or the fourth decade of life. Corticosteroids remain the

292 mainstream supportive approach to slow inflammation and the associated decline in muscle 293 strength and function [4]. However, steroids have their own adverse effects, and their 294 prescription is based on risk versus benefit to that specific patient and tolerance to the 295 medication. Exon-skipping gene therapy and cell-based strategies to replace the mutant DMD 296 gene are in development, but the desired outcome has not yet been achieved. In the 297 meantime, nutraceuticals can be considered potential strategies for immune modulation and 298 alleviating inflammation, as they are safer with lesser adverse effects [4]. Improvement of the 299 locomotor performances and mitochondrial respiration by 1,3-1,6 beta-glucans in zebra fish 300 model of muscular dystrophy [6] has already been reported.

In the current study, we focussed on a 1-3,1-6 beta glucan from the N-163 strain of the black yeast A. pullulans that has been reported to mitigate inflammation, evidenced by a decrease in anti-inflammatory markers and production of beneficial immuno-modulation [6-8]. The safety profile of N-163 beta glucan has been confirmed by the results.

305 Anti-inflammatory and anti-fibrotic outcomes: Circulating IL-6 is chronically elevated in 306 individuals with DMD [13], which has been reported to contribute to DMD-associated 307 cognitive dysfunction. IL-6 blockades have been advocated as a therapeutic approach for 308 DMD [14]. In the present study, IL-6 showed highest decrease in the N-163 Steroid -ve group 309 (Figure 2). While IL-6 is an acute inflammatory biomarker [14], IL-13 is a pro-fibrotic 310 biomarker [15] and was significantly decreased (Figure 3). Together with the TGF- $\beta$ 311 pathway, it is a major proinflammatory and pro-fibrotic cytokine responsible for the chronic 312 inflammatory response leading to replacement of the muscle by scar tissue or fibrosis, 313 resulting in muscle weakness and loss of muscle function [16]. IL-6 values matched that of 314 healthy controls and DMD patients who were treated with corticosteroids [17]. TGF- $\beta$  levels 315 also showed a significant decrease in the N-163 Steroid -ve group (Figure 4). Dystrophin 316 restoration of 20% expression [18,19] is considered the point of efficacy for a DMD therapy

317 [20] and was found to increase by 32.8% in both the treatment groups (Figure 5) of the 318 present study from baseline. We used serum dystrophin evaluation as recent evidence points 319 to the fact that the lack of dystrophin in the smooth muscle of blood vessels is the major 320 contributing factor to skeletal muscle pathogenesis in DMD and not the dystrophin deficiency 321 in skeletal or cardiac muscle [21]. Dystrophin is expressed in the tunica media of blood 322 vessels, especially in the muscular arteries. It has also been reported that the blood vessel-323 associated dystrophin is encoded by another gene than the skeletal muscle dystrophin gene 324 [22]. In a mdx mice model study, it was shown that dystrophin which was absent in the blood 325 vessels could be restored by induced genetic expression of full-length human dystrophin (h-326 dys) and this expression was able to restore the NO-dependent attenuation of  $\alpha$ -adrenergic 327 vasoconstriction in the exercising muscles, preventing further exacerbation of muscle fibre 328 necrosis [23]. In the present study, an increase in the plasma levels of dystrophin, which must 329 have been derived from vascular smooth muscle is evidence for the efficacy of beta glucans 330 as a potential adjunct to restore dystrophin in DMD.

331 Other biochemical markers of relevance: While haptoglobin and urine myoglobin did not 332 show significant differences, the increase in urine myoglobin in the N-163 Steroid +ve group 333 deserves more analysis concerning the underlying mechanism. Greater activity among 334 steroid-treated individuals may place their dystrophin-deficient muscles under greater 335 mechanical stress, predisposing them to further muscle fibre damage and consequent 336 myoglobinuria [24]. While titin and cystatin C decreased in the N-163 steroid +ve group and 337 in the control Steroid +ve group, there was an increase in CK, which is paradoxical, as 338 reports suggest that titin concentration correlates significantly with serum CK concentration 339 [25].

340 Muscle strength evaluation: There were three evaluations to assess muscle strength and 341 tone, done in a blinded manner by the same physiotherapist at baseline and post intervention.

342 Though the 6MWT and NSAA did not show any significant differences between the groups, 343 MRC grading showed improvement of muscle strength in 67% of the subjects in the 344 treatment group compared to 44% subjects in the control group, which is significant. The 345 limitation of this being a 45-day study is relevant to the muscle-strength and functional 346 evaluations, mandating the need for a longer study and follow-up duration. However, though 347 small, the improvement in MRC grading at 45 days could be again attributed to the immune 348 modulation effects of this disease-modifying supplement. The study shows proof of concept 349 that DMD could be tackled by the N-163 beta glucan from three aspects: decrease in 350 inflammation shown by decreased IL-6 and TNF- $\alpha$ , decrease in fibrosis evident by decreased 351 TGF- $\beta$  and IL-13 and, more importantly, restoration of dystrophin evident from a 32.8% 352 increase in dystrophin levels. These effects hold regardless of the use or non-use of steroids, 353 which is important, as this safety-proven food supplement can help DMD patients regardless 354 of steroid status.

355 Chronic inflammation being common to pathogenesis of all muscular dystrophies, 356 immunomodulatory treatment may benefit patients with diverse types of muscular dystrophy 357 [26]. Further, modulating the inflammatory response and inducing immunological tolerance 358 to de novo dystrophin expression is critical to the success of dystrophin-replacement 359 therapies [27]. The need to evaluate the muscles involved in respiratory function and 360 myocardium should be mentioned here, as they are the cause of mortality in most of the 361 DMD patients [1]. Though other dystrophies, such as limb girdle muscular dystrophy 362 (LGMD), do not involve respiratory or cardiac muscles, inflammatory overactivity is the 363 common pathophysiology among types of muscular dystrophy [26]. Once proven efficacious 364 for DMD, extending the beneficial application of the N-163 beta glucans to other dystrophies 365 such as LGMD can be considered.

366

367 DMD is a rare genetic disease with a maximum life expectancy of up to fourth decade, with 368 the majority of victims dying in their late twenties to thirties. The average lifespan at birth, 369 which was 20+ years for those born in or before 1970, has gradually increased by 10-15370 years for those born and diagnosed with DMD in the 1980s and 1990s. This increase is 371 attributed to better or early ventilatory assistance, steroid usage and cardiac care [28.29], 372 which are only supportive interventions. With the gene therapies approved recently, there is a 373 hope of additional progress and increase in lifespan [30]. Though these gene therapies (such 374 as exon skipping) address the root cause by splicing out selected exons from the pre-mRNA 375 at or next to the mutation site, generating a translatable transcript from the mutant dystrophin 376 gene leading to dystrophin expression [30, 31], they are still marred by challenges such as 377 delivery of gene-editing components throughout the musculature and mitigation of possible 378 immune responses [32]. The current need, therefore, is to modulate the immune system and 379 control the inflammation and ensuing fibrosis to delay the progression of the disease. The 380 earlier usage of steroids in a regular manner was later changed to intermittent usage [33] with 381 regimens varying between institutes; now, newer steroids with lesser adverse effects are in 382 various stages of progress towards clinical applications [34]. In this background, the safety of 383 this N-163-produced beta glucan food supplement without adverse reactions is to be 384 considered an indispensable value addition. Targeting the inflammation component (the 385 criteria for selecting this supplement for this study) having yielded beneficial outcomes, 386 additional studies on this characteristic could be of value to possibly extending their 387 application for other neuroinflammatory diseases, such as multiple sclerosis.

The limitations of the study include uneven distribution of subjects, broad age range (5-19 years) and short follow-up (only 45 days); improvements in muscle function over the course of the study showed variability that may have been due to the level of sensitivity to change of functional assessments during the disease progression in the age group. Among the 27

392 subjects, two-thirds were ambulatory and the remaining non-ambulatory; the evaluation 393 criteria differences must be kept in mind, which may show equivalent quantification among 394 all DMD patients at different stages of disease severity when non-invasive myograms to 395 measure the individual muscles accurately could be undertaken. Further, the steroid dose was 396 not uniform and fell into a broad range (6-24 mg). Also, the consumption of steroids vs those 397 who did not consume them or those who had stopped steroids after an initial duration of 398 consumption, as well as regimen variation, are to be considered while interpreting the 399 outcomes. All these aspects mandate the need for larger randomized clinical trials of longer 400 duration to validate this supplement as a treatment.

## 401 **Conclusion:**

402 N-163 beta glucan with and without steroids helped decrease IL-6, TGF- $\beta$  and IL-13 and 403 increase dystrophin levels along with improvement of muscle strength in subjects with DMD 404 in this clinical study. Thus, N-163 beta glucan is a safe and effective potential therapeutic 405 adjunct for patients with DMD. While the benefits documented may help slow the rate of 406 progression of this devastating disease, confirmation by longer and larger studies will help 407 establish this agent for routine clinical application as a disease-modifying agent with the 408 potential to help prolong the lifespan of DMD patients. After such validation, extending its 409 application to other dystrophies such as LGMD could be considered, and further in-depth 410 research in neuroinflammatory diseases are likely to shed light on the mechanism of action, 411 leading to additional beneficial applications.

412

413

414

416	
417	
418	
419	Abbreviations:
420	DMD: Duchenne muscular dystrophy
421	CK: Creatinine kinase
422	TNF-α: tumour necrosis factor - Alpha
423	MRC: Medical research council
424	NLR: Neutrophil-to-lymphocyte ratio
425	LCR: Lymphocyte-to-CRP ratio
426	LeCR: Leukocyte-to-CRP ratio
427	NASH: Non-alcoholic steatohepatitis
428	6MWT: Six-minute walk test
429	NSAA: North Star Ambulatory Assessment
430	LGMD: Limb girdle muscular dystrophy
431	
432	References:

433 1	1.	Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones
434		K, Krishnamurthi R, Feigin V. Prevalence of muscular dystrophies: a systematic
435		literature review. Neuroepidemiology. 2014;43(3-4):259-68.
436 2	2.	Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D.
437		Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a
438		multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials.
439		2019;20(1):637.

- 440 3. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield
- LM, Woodcock J. Immune-mediated pathology in Duchenne muscular dystrophy. Sci
  Transl Med. 2015;7(299):299rv4.
- 443 4. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for
  444 Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725.
- 5. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Spotlight on
   Research: Optimizing Steroid Treatment for Duchenne Muscular Dystrophy
- 447 <u>https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-</u>
- 448 <u>treatment-duchenne-muscular-dystrophy</u> (Accessed: December 13, 2021).
- 6. Licitra R, Marchese M, Brogi L, Fronte B, Pitto L, Santorelli FM. Nutraceutical
  Screening in a Zebrafish Model of Muscular Dystrophy: Gingerol as a Possible Food
  Aid. Nutrients. 2021;13(3):998.
- 452 7. Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R,
  453 Preethy S, Abraham SJK. Immune and metabolic beneficial effects of Beta 1,3-1,6
  454 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle455 aged Japanese men: An exploratory study. medRxiv 2021.08.05.21261640; doi:
  456 10.1101/2021.08.05.21261640
- Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan
   M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK. Beneficial effects of the AFO 202 and N-163 strains of Aureobasidium pullulans produced 1,3-1,6 beta glucans on
   non-esterified fatty acid levels in obese diabetic KKAy mice: A comparative
   study.bioRxiv 2021.07.22.453362; doi: 10.1101/2021.07.22.453362
- 9. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S,
  Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of Aureobasidium
  pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM-

465 animal model of non-alcoholic steatohepatitis. bioRxiv 2021.07.08.451700; doi:

466 10.1101/2021.07.08.451700

- 467 10. MRC Muscle Scale. <u>https://mrc.ukri.org/research/facilities-and-resources-for-</u>
   468 researchers/mrc-scales/mrc-muscle-scale/ (Accessed: December 13, 2021).
- 469 11. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL,
- Atkinson L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome
  measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500-10
- 472 12. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Manzur A, Muntoni F;
- 473 North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a474 functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.

475 Physiother Res Int. 2012;17(2):101-9. doi: 10.1002/pri.520.

- 476 13. Stephenson KA, Rae MG, O'Malley D. Interleukin-6: A neuro-active cytokine
  477 contributing to cognitive impairment in Duchenne muscular dystrophy? Cytokine.
  478 2020;133:155134.
- 479 14. Mammen AL, Sartorelli V. IL-6 Blockade as a Therapeutic Approach for Duchenne
  480 Muscular Dystrophy. EBioMedicine. 2015;2(4):274-5.
- 481 15. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Muñoz-
- 482 Cánoves P. Aberrant repair and fibrosis development in skeletal muscle. Skelet
  483 Muscle. 2011;1(1):21.
- 484 16. Ceco E, McNally EM. Modifying muscular dystrophy through transforming growth
  485 factor-β. FEBS J. 2013;280(17):4198-209.
- 486 17. Pelosi L, Berardinelli MG, De Pasquale L, Nicoletti C, D'Amico A, Carvello F,
- 487 Moneta GM, Catizone A, Bertini E, De Benedetti F, Musarò A. Functional and
  488 Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor
  489 Blockade. EBioMedicine. 2015 Feb 26;2(4):285-93.

- 490 18. Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda S, Yokota T, Aoki Y.
- 491 Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of
- 492 Therapeutic Approaches. J Pers Med. 2019;9(1):1.
- 493 19. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark
  494 KR. Gene therapy for muscular dystrophy: lessons learned and path forward.
- 495 Neurosci Lett. 2012;527(2):90-9.
- 496 20. Wells DJ. What is the level of dystrophin expression required for effective therapy of
  497 Duchenne muscular dystrophy? J Muscle Res Cell Motil. 2019;40(2):141-150.
- 498 21. Gajendran, N. The root cause of Duchenne muscular dystrophy is the lack of
  499 dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per se
  500 *F1000Research* 2018; **7**: 1321.
- 22. Augier N, Boucraut J, Léger J, Anoal M, Nicholson LV, Voelkel MA, Léger JJ,
  Pellissier JF. A homologue of dystrophin is expressed at the blood vessel membrane
  of DMD and BMD patients: immunological evidence. J Neurol Sci. 1992
  Feb;107(2):233-8.
- 505 23. Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K, Ueno H, Suzuki
  506 M, Araki K, Yamamura K, Miwa T, Dickson G, Thomas GD, Miike T. Smooth
  507 muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
  508 Hum Mol Genet. 2006 Jul 15;15(14):2266-75.
- 24. Awano H, Matsumoto M, Nagai M, Shirakawa T, Maruyama N, Iijima K, Nabeshima
  YI, Matsuo M. Diagnostic and clinical significance of the titin fragment in urine of
  Duchenne muscular dystrophy patients. Clin Chim Acta. 2018;476:111-116.
- 512 25. Garrood P, Eagle M, Jardine PE, Bushby K, Straub V. Myoglobinuria in boys with
  513 Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscul Disord. 2008
  514 ;18(1):71-3.

515	26. Raimondo TM, Mooney DJ. Anti-inflammatory nanoparticles significantly improve
516	muscle function in a murine model of advanced muscular dystrophy. Sci Adv.
517	2021;7(26):eabh3693.

- 518 27. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a
  519 nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse
  520 model of Duchenne muscular dystrophy. PLoS One. 2012;7(11):e49350.
- 521 28. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M,
  522 Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular
  523 dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79
- 29. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, Perrouin Verbe B.
- 525 Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM
- 526 Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med.
  527 2013;56(6):443-54.
- 30. Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular
  Dystrophy. Mol Ther. 2018;26(10):2337-2356.
- 530 31. Echevarría L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne
  531 muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163-R172.
- 32. Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for
  Duchenne muscular dystrophy. Gene Ther. 2020;27(9):407-416. doi: 10.1038/s41434020-0156-6.
- 33. Olson EN. Toward the correction of muscular dystrophy by gene editing. Proc Natl
  Acad Sci U S A. 2021;118(22):e2004840117.
- 537 34. Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E.
  538 Standard of care versus new-wave corticosteroids in the treatment of Duchenne

539	muscular	dystrophy:	Can	we	do	better?	Orphanet	J Rare	Dis.	2021;16(1):11	7. doi:

- 540 10.1186/s13023-021-01758-9.
- 541 35. Boziki MK, Kesidou E, Theotokis P, Mentis AA, Karafoulidou E, Melnikov M,
  542 Sviridova A, Rogovski V, Boyko A, Grigoriadis N. Microbiome in Multiple
  543 Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci.
  544 2020;10(4):234.
- 545 36. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G,
- 546 Iwasaki M, Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK. Beneficial
- 547 reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloids-
- 548 producing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism
- and potentials in neurodegenerative diseases. medRxiv 2021.10.26.21265505; doi:
- 550 10.1101/2021.10.26.21265505
- 551
- 552
- 553
- 554
- 555

556

557

- 558
- 559

- 500
- 561

562			
563			
564			
565			
566			
567			
568			
569			
570			

# 571 Tables and Figures

Table 1: Demographics and baseline characteristi	cs	
--	----	--

	Subject	Age in years	Weight in kgs	Exon Deletion	Clinical Diagnosis	Ambulatory/ Non- Ambulatory	Dose of Deflaz acort (mg/da y)	Duration of consump tion of steroids
Control Steroid -ve	1	6-10	12	10 & 11	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	2	6-10	27	46-55	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	3	16-20	48		Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	4	11-15	60	8 to 48	Duchenne Muscular Dystrophy	Non- Ambulatory	NA	NA

					(DMD)			
	5	11-15	55	10- 11/Dup	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	1	16-20	65	44	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	6	8 years
Control	2	6-10	25	5&6	Duchenne Muscular Dystrophy (DMD)	Ambulatory	12	2.5 months
+ve	3	6-10	21	49-52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	9	11 months
	4	11-15	48	52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	6 years
N-163 Steroid -ve	1	6-10	28	48-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	2	1-5	10	45-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	3	11-15	38	45-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	4	6-10	45	60	Becker muscular dystrophy (BMD)	Ambulatory	NA	NA
	5	6-10	39	10-11/ Dup	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	6	6-10	21	49-52	Duchenne Muscular	Ambulatory	NA	NA

					Dystrophy (DMD)			
	7	11-15	39	43	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	8	11-15	40		Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	9	6-10	22	44- 57/Dup	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	1	1-5	18	48-50	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	6	5 months
	2	11-15	59	17	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	2 months
N-163 Steroid +ve	3	11-15	40	60	Becker muscular dystrophy (BMD)	Ambulatory	6	6 years
	4	6-10	20	48-52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	3 years
	5	6-10	36	48-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	3 years

578			
579			
580			
581			
582			
583			
584			
585			

# Table 2: Details of the ELISA kits along with their sensitivity

S.No	Human Antibody	Purchased from	Catalogue No.	Limit of detection/Sensitivity
1	Interleukin-6 (IL6)	Seimens	10995080	3.0 pg/mL
2	Myoglobin	Diagnostic Automation Inc	1667-18	270 pg/mL
3	Dystrophin (DMD)	KINESISDx	K12-1446	0.042 ng/mL
4	Titin (TTN)	Mybiosource	MBS762344	0.094 ng/mL
5	Creatinine Kinase (CK)	Agappe	51404001	2.0 U/L
6	IL-13	Diaclone	850080048	1.5 pg/mL
7	TGF-β	Diaclone	650010096	8.6 pg/mL
8	Cystatin C	Siemens	E0001V	0.06 µg/L
9	TNF-a	Siemens	LKNF1	6.23 pg/mL
10	Haptoglobin	Seimens	OSAV09	0.26 ng/mL

592			
593			
594			
595			
596			
597			

598

Table 3: Medical research council (MRC) grading of muscle power in the study groups

Subject	Ambulatory/Non- ambulatory	Baseline	Post-intervention	Progression			
Control group							
1	Ambulatory	151	165	Improved			
2	Ambulatory	133	162	Improved			
3	Non-ambulatory	70	80	Improved			
4	Non-ambulatory	164	164	No change			
5	Non-ambulatory	109	106	Worsened			
6	Non-ambulatory	102	105	Improved			
7	Non-ambulatory	117	115	Worsened			
8	Non-ambulatory	110	109	No change			
9	Non-ambulatory	105	102	Worsened			
1	Ambulatory	134	133	Worsened			
1	Ambulatory	134	133	Worsened			
2	Ambulatory	140	103	Improved			
3	Ambulatory	119	131	Improved			
4	Ambulatory	127	136	Improved			
5	Ambulatory	154	160	Improved			
6	Ambulatory	158	168	Improved			
7	Non-ambulatory	102	119	Improved			
8	Non-ambulatory	116	117	Improved			
9	Non-ambulatory	127	127	No change			
10	Non-ambulatory	120	131	-			
			151	Improved			
11	Non-ambulatory	96	107	Improved Improved			

13	Non-ambulatory	117	113	Worsened
14	Non-ambulatory	108	108	No change
15	Non-ambulatory	103	107	Improved
16	Non-ambulatory	145	148	Improved
17	Non-ambulatory	93	119	Improved
18	Non-ambulatory		Test couldn't be perfor	rmed

605 Figures:



### 607 Figure 1: CONSORT flow diagram of the trial





Figure 2: IL-6 showed the most significant decrease in the N-163 Steroid -ve group compared







Figure 3: Levels of IL-13 levels showed statistically significant increase in control groups

and decrease in treatment groups (\*p-value significance < 0.05)





618 Figure 4: Levels of TGF-β showed significant decrease in the N-163 Steroid -ve group 619 compared to other groups (\*p-value significance < 0.05)





Figure 5: Levels of dystrophin showed significant increase in the N-163 Steroid -ve group
compared to other groups (\*p-value significance < 0.05)</li>

624









Figure 7: Levels of Creatinine kinase (CK), Titin, Cystatic-C, Urine myoglobin, Haptoglobin

- and TNF- $\alpha$  between control and treatment group (N-163), pre- and post-intervention (\*p-
- 633 value significance < 0.05)

634

635



Figure 8: MRC muscle grading, 6MWT and NSAA results between control and treatment



639

640